Stoxline.com

Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Progenity Inc (PROG)

1.69   0.08 (4.97%) 01-16 19:13
Open: 1.577 Pre. Close: 1.61
High: 1.72 Low: 1.5101
Volume: 11,852,488 Market Cap: 277M
Progenity, Inc., a biotechnology company, provides develops and commercializes molecular testing products in the United States. It offers Innatal, a noninvasive prenatal screening test offered to women early in pregnancy to screen for chromosome abnormalities, such as down syndrome, trisomy 18, trisomy 13, and sex chromosome disorders through the analysis of cell-free DNA; Preparent that screens for carrier status of hereditary diseases prior to or early in pregnancy; and Riscover, a hereditary cancer screen that analyzes 31 genes associated with inherited risk of 12 types of cancers, including the BRCA1/2 genes for hereditary breast, ovarian, colorectal, endometrial, pancreatic, and other cancer syndromes, as well as for the five genes associated with Lynch syndrome. The company also provides Resura, a noninvasive prenatal test for families at risk for rare single gene disorders; and Preecludia, a preeclampsia rule-out test. In addition, it offers anatomic and molecular pathology tests, and COVID-19 PCR testing services, as well as test products that includes chromosomal microarray for pregnancy loss, which evaluates the genetic cause of miscarriage; maternal serum screening for chromosomal disorders; and preimplantation genetic testing for use with artificial reproductive technologies. Further, the company develops therapeutic solutions for gastrointestinal-related disorders, such as PGN-001, PGN-300, PGN-600, and PGN-OB2. It also owns and operates laboratory. Progenity, Inc. was formerly known as Ascendant MDX, Inc. and changed its name to Progenity, Inc. in November 2013. The company was founded in 2010 and is headquartered in San Diego, California.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 1.724 - 1.735 1.735 - 1.746
Low: 1.485 - 1.498 1.498 - 1.51
Close: 1.668 - 1.69 1.69 - 1.711

Technical analysis

as of: 2022-01-15 8:49:03 PM
Overall:       
Stoxline posted a NEUTRAL today, upgraded from lower rating. Current trend continues, but could change at anytime. It is not a good time to buy or sell.
Target: Six months: 2.65     One year: 3.20
Support: Support1: 1.51    Support2: 1.26
Resistance: Resistance1: 2.27    Resistance2: 2.74
Pivot: 1.97
Moving Average: MA(5): 1.77     MA(20): 2.08
MA(100): 2.31     MA(250): 3.07
MACD: MACD(12,26): -0.27     Signal(9): -0.26
Stochastic oscillator: %K(14,3): 7.77     %D(3): 6.50
RSI: RSI(14): 33.07
52-week: High: 7.86  Low: 0.66  Change(%): -72.8
Average Vol(K): 3-Month: 4822230  10-Days: 1007264

Price, moving averages and Bollinger Bands

Price and moving averages has closed below its Short term moving average. Short term moving average is currently below mid-term; AND below long term moving averages. From the relationship between price and moving averages; we can see that: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.
PROG has closed above bottom band by 10.9%. Bollinger Bands are 53.5% narrower than normal. The narrow width of the bands suggests low volatility as compared to PROG's normal range. The bands have been in this narrow range for 11 bars. This is a sign that the market may be about to initiate a new trend.

Headline News

Sun, 16 Jan 2022
Progenity, Inc. (NASDAQ:PROG) Given Consensus Rating of "Hold" by Analysts - MarketBeat

Wed, 12 Jan 2022
Zacks Investment Research Lowers Progenity (NASDAQ:PROG) to Hold - MarketBeat

Mon, 10 Jan 2022
Analysts Anticipate Progenity, Inc. (NASDAQ:PROG) Will Announce Earnings of -$0.13 Per Share - MarketBeat

Wed, 05 Jan 2022
Progenity Announces Acceptance of Two Abstracts on Treatment of Gastrointestinal Disorders at ECCO'22 - GlobeNewswire

Mon, 03 Jan 2022
Progenity to Participate in the H.C. Wainwright BIOCONNECT Virtual Conference - The Bakersfield Californian

Mon, 27 Dec 2021
Where Will Progenity Inc (PROG) Stock Go Next After It Is Down 22.30% in a Week? - InvestorsObserver

Financial Analysis

Growth NA
Growth measures the growth of both a company's revenue and net income. it tells investors how fast a company is growing.
Profitability NA
Profitability measures a company’s ability to generate earnings as compared to its expenses and other relevant costs.
Solvency NA
Solvency measures a company's ability to meet its long-term debts. Acceptable solvency ratios will vary from industry to industry.
Efficiency NA
Efficiency measures the strength of a company's return on invested capital. It can identify business that are better managed or not.
Price to Book Value: Underperform Discounted cash flow: Outperform
Return on Assets: Underperform Price to Earnings: Underperform
Return on Equity: Outperform Debt to Equity: Underperform
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. (M)
Shares Float (M)
% Held by Insiders
% Held by Institutions
Shares Short (K)
Shares Short P. Month (K)

Stock Financials

EPS
EPS Est This Year
EPS Est Next Year
Book Value (p.s.)
Profit Margin
Operating Margin
Return on Assets (ttm)
Return on Equity (ttm)
Qtrly Rev. Growth
Gross Profit (p.s.) -0.144
Sales Per Share 0.565
EBITDA (p.s.) -1.551
Qtrly Earnings Growth
Operating Cash Flow (M)
Levered Free Cash Flow (M)

Stock Valuations

PE Ratio
PEG Ratio
Price to Book value
Price to Sales 2.99
Price to Cash Flow

Stock Dividends

Dividend
Forward Dividend
Dividend Yield
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
7 Binary Options
Your Ad Here
android_stock_chart
Stock Chart
stoxline_lite
Stoxline Lite
stoxline_pro
Stoxline Pro
Option_Calculator
Option Calculator
(c) 2006-2020 Stoxline.com | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Stoxline.com nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the Stoxline.com web site, a user agrees not to redistribute the information found therein.